ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AbbVie and RemeGen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AbbVieRemeGen
studies on the registry2,25183
open to participants now13342
phase 3 studies under way7418
reach primary completion within a year905
programswith a study of their own in two years70+8 named only10

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAbbVieRemeGen
Phase 1

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
00%
Phase 2

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%

RemeGen: 5 of its 10 programs at phase 2

  1. Anti-c-Met/MMAE ADC RC108phase 2
  2. ABBV-1480phase 2
  3. RC278phase 2
  4. RC288phase 2
  5. telisotuzumab adizutecanphase 2
50%
Phase 3

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%

RemeGen: 5 of its 10 programs at phase 3

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. telitaciceptphase 3
  4. RC28-E proteinphase 3
  5. tislelizumabphase 3
50%
Approved, new studies

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
RemeGen3 readouts · 3 phase 3·

RemeGen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. disitamab vedotinphase 3 · Dec 0 · NCT06221748
  2. telitaciceptphase 3 · Dec 31 · NCT07249632
····

RemeGen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. RC148phase 3 · May 12 · NCT07462143
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AbbVie

New programs 5

  • [11C]ABBV-112iearly phase 1 · first study · Nov 6
  • ABBV-7828phase 1 · first study · Sep 28
  • ABBV-1162phase 1 · first study · Sep 16
  • ABBV-253phase 1 · first study · Sep 1 · Carcinoma, Non-Small-Cell Lung
  • NOA LIFTphase 3 · first study · Aug 27

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

RemeGen

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionAbbVieRemeGen
Carcinoma, Non-Small-Cell Lungboth · compare here

AbbVie in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. ABBV-253phase 1
  4. azirkitugphase 1
  5. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

RemeGen in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. tislelizumabphase 3
  4. Anti-c-Met/MMAE ADC RC108phase 2
  5. ABBV-1480phase 2

and 1 more — sign in to see them all

Their studies: RemeGen’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsboth · compare here

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

RemeGen in Colorectal Neoplasms: 2 programs

  1. RC148phase 3
  2. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Colorectal Neoplasms in search

Breast Neoplasmsboth · compare here

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

RemeGen in Breast Neoplasms: 2 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3

Their studies: RemeGen’s studies of Breast Neoplasms in search

Macular Degenerationboth · compare here

AbbVie in Macular Degeneration: 3 programs

  1. surabgene lomparvovecphase 3
  2. Ranibizumab Controlphase 3
  3. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Macular Degeneration in search

RemeGen in Macular Degeneration: 1 program

  1. RC28-E proteinphase 3

Their studies: RemeGen’s studies of Macular Degeneration in search

Neoplasmsboth · compare here

RemeGen in Neoplasms: 1 program

  1. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Neoplasms in search

Carcinoma, Hepatocellularboth · compare here

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

RemeGen in Carcinoma, Hepatocellular: 2 programs

  1. tislelizumabphase 3
  2. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Carcinoma, Hepatocellular in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

AbbVie in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-711phase 1

Their studies: AbbVie’s studies of Squamous Cell Carcinoma of Head and Neck in search

RemeGen in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Squamous Cell Carcinoma of Head and Neck in search

Colonic Neoplasmsboth · compare here

AbbVie in Colonic Neoplasms: 1 program

  1. RC148no phase

Their studies: AbbVie’s studies of Colonic Neoplasms in search

RemeGen in Colonic Neoplasms: 1 program

  1. RC148phase 3

Their studies: RemeGen’s studies of Colonic Neoplasms in search

Diabetic Retinopathyboth · compare here

AbbVie in Diabetic Retinopathy: 1 program

  1. surabgene lomparvovecphase 3

Their studies: AbbVie’s studies of Diabetic Retinopathy in search

RemeGen in Diabetic Retinopathy: 1 program

  1. RC28-E proteinphase 3

Their studies: RemeGen’s studies of Diabetic Retinopathy in search

Lupus Erythematosus, Systemicboth · compare here

AbbVie in Lupus Erythematosus, Systemic: 1 program

  1. ABBV-519phase 1

Their studies: AbbVie’s studies of Lupus Erythematosus, Systemic in search

RemeGen in Lupus Erythematosus, Systemic: 1 program

  1. telitaciceptphase 3

Their studies: RemeGen’s studies of Lupus Erythematosus, Systemic in search

Sjogren's Syndromeboth · compare here

AbbVie in Sjogren's Syndrome: 1 program

  1. ravagalimabphase 2

Their studies: AbbVie’s studies of Sjogren's Syndrome in search

RemeGen in Sjogren's Syndrome: 1 program

  1. telitaciceptphase 3

Their studies: RemeGen’s studies of Sjogren's Syndrome in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AbbVie 54 of 70 · RemeGen 5 of 10 programs (15 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8).